This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

From the outset, Wolozin and colleagues¹ assert that hypercholesterolemia is associated with increased risk of Alzheimer disease (AD). That premise, of course, sets up their study hypothesis regarding the putative protective effects of statin-class lipid-lowering medications on the development of AD. However, while recent research suggests a role for lipids in AD, the manner in which the article deals with this topic is, at best, misleading. Molecular studies are revealing a complex but indirect role for cholesterol transport and membrane dynamics in the pathophysiology of AD. Too little rather than too much cholesterol in neural membranes appears to increase vulnerability to dysfunction.² Similarly, low, not high, serum cholesterol concentrations have been found to predict cognitive decline in prospective studies of aging American twins³ and elderly Finns.⁴ Thus, only a fraction of published evidence supports the article's opening premise.⁵

In any case, the research presented by Wolozin and colleagues should be . . . [Full Text of this Article]